WHY ORAL VACCINES

Hands-with-pipette
Delivery
Taking-a-Pill

Esperovax’s proprietary oral mRNA vaccine platform can provide billions of doses annually that can be delivered to patients by mail and consumed without health professionals present.

Reduce and Prevent Disease

Vaccination is universally accepted as the most inexpensive and effective method for reducing and preventing human disease. Yet vaccines still do not exist for many concerning diseases, including RSV, Norovirus, HIV, and many other infections.  And for diseases that have approved vaccines like seasonal influenza, much of the population in the United States and across the world go unvaccinated each year.

Most vaccinations today are delivered through direct injection by health care professionals. This limits the number of patients that can be immunized. Also, injections can be painful, expensive, and time-consuming, making it difficult to scale up and achieve broad adoption. The COVID-19 pandemic underscores the need to develop and distribute vaccines by innovative and rapid means.  Esperovax’s oral mRNA vaccine platform addresses many of the concerns and limitations of injectable vaccines, and can significantly expand vaccination rates across the world at a fraction of the cost.

Why Is Respiratory Syncytial Virus (RSV) a priority for vaccine manufacturers?

In the U.S., nearly all children become infected with RSV by age 2, with up to 125,000 of them hospitalized each year. Globally, RSV affects an estimated 64 million people and causes 160,000 deaths each year.
Source: The National Institutes of Health

Technology

Esperovax has developed a robust, proprietary oral mRNA vaccine platform. Our vaccines are better, safer and more cost-effective than injectables.

Pipeline

Our Egress™ oral biologics platform holds great potential for preventing and treating infections in humans and animals in a revolutionary way.